FAQs about Relyvrio

Category: Relyvrio

The U.S. Food and Drug Administration (FDA) approved Relyvrio for the treatment of adults with amyotrophic lateral sclerosis in 2022. The decision came just a few months after the medication gained its first approval in Canada, where it is sold under the brand name Albrioza.

Category: Relyvrio

Relyvrio was approved for the treatment of amyotrophic lateral sclerosis (ALS) after clinical trials showed it could slow declines in the ability to function and extend survival by several months. However, like other available ALS therapies, Relyvrio generally cannot reverse or reduce symptoms that already existed at the time of the treatment’s start.

Category: Relyvrio

According to data from CENTAUR, the Phase 2 clinical trial that supported Relyvrio’s approval, the medication significantly slowed disease progression compared with a placebo after six months of treatment. Still, each patient has a different experience with amyotrophic lateral sclerosis and responses to treatment also will differ, so there’s no way of knowing exactly when someone will start to benefit from Relyvrio.

Category: Relyvrio

While no interaction between alcohol and Relyvrio has been reported, it is recommended that patients discuss with their care team if and how much alcohol is safe to drink while on the medication.

Category: Relyvrio

Relyvrio is not a cure for amyotrophic lateral sclerosis (ALS). The medication can slow, but will not stop disease progression, and patients will continue to experience worsening symptoms and be less able to perform their daily activities as time goes on.